Genetics of Anthracycline-Associated Cardiotoxicity.
anthracycline
anthracycline associated cardiotoxicity
cardio-oncology
genetic testing
genetics
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2022
2022
Historique:
received:
01
02
2022
accepted:
24
03
2022
entrez:
9
5
2022
pubmed:
10
5
2022
medline:
10
5
2022
Statut:
epublish
Résumé
Anthracyclines are a major component of chemotherapies used in many pediatric and adult malignancies. Anthracycline-associated cardiotoxicity (ACT) is a dose-dependent adverse effect that has substantial impact on morbidity and mortality. Therefore, the identification of genetic variants associated with increased risk of ACT has the potential for significant clinical impact to improve patient care. The goal of this review is to summarize the current evidence supporting genetic variants associated with ACT, identify gaps and limitations in current knowledge, and propose future directions for incorporating genetics into clinical practice for patients treated with anthracyclines. We will discuss mechanisms of ACT that could be illuminated by genetics and discuss clinical applications for the cardiologist/cardio-oncologist.
Identifiants
pubmed: 35528837
doi: 10.3389/fcvm.2022.867873
pmc: PMC9068960
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
867873Informations de copyright
Copyright © 2022 Al-Otaibi, Weitzman, Tahir and Asnani.
Déclaration de conflit d'intérêts
AA has consulted for Sanofi and AstraZeneca, serves as an advisory board member for Cytokinetics, and serves as the principal investigator for a sponsored research agreement with Genentech. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Curr Drug Metab. 2001 Dec;2(4):355-66
pubmed: 11766987
J Am Coll Cardiol. 2018 May 22;71(20):2291-2292
pubmed: 29773156
Br J Haematol. 2013 Oct;163(2):205-13
pubmed: 23927520
N Engl J Med. 2016 Dec 15;375(24):2349-2358
pubmed: 27959714
Circulation. 2022 Jan 25;145(4):279-294
pubmed: 34874743
Circulation. 2019 Jul 2;140(1):31-41
pubmed: 30987448
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Proc Natl Acad Sci U S A. 1988 May;85(10):3585-9
pubmed: 2897122
Pharmacol Rev. 2006 Jun;58(2):244-58
pubmed: 16714487
Genet Med. 2018 Jun;20(6):622-629
pubmed: 29261188
N Engl J Med. 2014 Jun 19;370(25):2418-25
pubmed: 24941179
BMC Cancer. 2012 Aug 31;12:381
pubmed: 22938713
J Chemother. 2012 Oct;24(5):285-91
pubmed: 23182048
Sci Rep. 2016 May 04;6:25333
pubmed: 27142468
Circulation. 2007 Jul 31;116(5):506-14
pubmed: 17638931
Invest New Drugs. 2017 Jun;35(3):375-385
pubmed: 28283780
Eur J Heart Fail. 2018 Apr;20(4):803-806
pubmed: 29057560
Pharmacogenomics J. 2016 Nov;16(6):530-535
pubmed: 26345518
Biochem Biophys Res Commun. 2005 Aug 5;333(3):754-62
pubmed: 15963465
Cancer Epidemiol Biomarkers Prev. 2001 Dec;10(12):1239-48
pubmed: 11751440
J Clin Oncol. 2012 May 1;30(13):1415-21
pubmed: 22124095
Nat Med. 2012 Nov;18(11):1639-42
pubmed: 23104132
Pharmacogenomics. 2015;16(10):1065-76
pubmed: 26230641
Cancer. 2013 Oct 1;119(19):3555-62
pubmed: 23861158
BMJ. 2009 Dec 08;339:b4606
pubmed: 19996459
IUBMB Life. 2001 Jul;52(1-2):83-8
pubmed: 11795600
Circulation. 2016 Apr 26;133(17):1668-87
pubmed: 26984939
Eur J Cancer. 2006 Dec;42(18):3191-8
pubmed: 16987655
Ann Oncol. 2007 Jun;18 Suppl 6:vi173-8
pubmed: 17591817
J Clin Oncol. 2014 Mar 1;32(7):647-53
pubmed: 24470002
Eur J Heart Fail. 1999 Dec;1(4):363-9
pubmed: 10937949
J Clin Oncol. 2012 May 1;30(13):1422-8
pubmed: 21900104
Cancer. 2020 Sep 1;126(17):4051-4058
pubmed: 32413235
Cell Biol Int. 2012 Jan;36(1):79-86
pubmed: 21929509
Circulation. 2005 Dec 13;112(24):3754-62
pubmed: 16330681
Pharmacol Rev. 2004 Jun;56(2):185-229
pubmed: 15169927
Eur J Heart Fail. 2003 Aug;5(4):463-8
pubmed: 12921807
J Am Coll Cardiol. 2017 May 16;69(19):2466-2468
pubmed: 28494986
Mol Pharmacol. 2009 May;75(5):1117-26
pubmed: 19233900
Blood. 2003 Oct 1;102(7):2574-80
pubmed: 12805055
J Clin Invest. 2014 Feb;124(2):617-30
pubmed: 24382354
Science. 1984 Oct 26;226(4673):466-8
pubmed: 6093249
J Am Soc Echocardiogr. 2014 Sep;27(9):911-39
pubmed: 25172399
Nat Genet. 2015 Sep;47(9):1079-84
pubmed: 26237429
Ann Oncol. 2004 Mar;15(3):440-9
pubmed: 14998846
Genet Med. 2014 Aug;16(8):601-8
pubmed: 24503780
Circulation. 2018 Dec 11;138(24):2852-2854
pubmed: 30565988
Cancer. 2012 Apr 1;118(7):1856-67
pubmed: 21887680
J Am Coll Cardiol. 2004 Nov 16;44(10):2019-26
pubmed: 15542286
Nat Genet. 2018 Sep;50(9):1219-1224
pubmed: 30104762
Methods Enzymol. 2005;400:57-75
pubmed: 16399343
Pediatr Blood Cancer. 2013 Aug;60(8):1375-81
pubmed: 23441093
BMC Cancer. 2010 Jun 29;10:337
pubmed: 20587042
Drug Metab Dispos. 1980 May-Jun;8(3):152-6
pubmed: 6104578
Genet Med. 2015 Jun;17(6):444-51
pubmed: 25232854
J Clin Oncol. 2016 Mar 10;34(8):863-70
pubmed: 26811534